加载中
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
收盘时
US$3.02
−US$0.36 · -10.65%
盘后
US$3.02
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
日内区间
当前US$3.02
52周区间
当前US$3.02
盘中时间采用ET。市场数据可能有所延迟。
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
日内区间
当前US$3.02
52周区间
当前US$3.02
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 714.5万 USD | 2598.3万 USD | 2435.4万 USD | 1521.6万 USD | 112万 USD |
| 销货成本 | 76万 USD | 5405.4万 USD | 5173.8万 USD | 3399.7万 USD | 1967万 USD |
| 毛利 | 638.5万 USD | −2807.1万 USD | −2738.4万 USD | −1878.1万 USD | −1855万 USD |
| 研究与开发 | 9096.3万 USD | 5103万 USD | 4892.9万 USD | 3266.2万 USD | 1967万 USD |
| 销售、一般及管理费用 | 2982.2万 USD | 3674.9万 USD | 4454.9万 USD | 4017.6万 USD | 1851.1万 USD |
| 营业费用 | 1.21亿 USD | 3938.7万 USD | 4454.9万 USD | 4390万 USD | 9266.7万 USD |
| 利息收入 | 623.1万 USD | 392.5万 USD | 640万 USD | 239.8万 USD | 1.3万 USD |
| 利息支出 | — | 15.4万 USD | 23.1万 USD | 23万 USD | 66.5万 USD |
| 折旧和摊销 | 7.9万 USD | 19.3万 USD | 16.9万 USD | 15.9万 USD | 10.5万 USD |
| 营业利润 | −1.14亿 USD | −6745.8万 USD | −7193.3万 USD | −6268.1万 USD | −1.11亿 USD |
| 净利润 | −2059.6万 USD | −6369.1万 USD | −6576.5万 USD | −6051.3万 USD | −1.1亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.33
上涨空间 175.83%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2021年8月27日 | 15:1 | — | — |
股票拆分 | 2021年8月18日 | 2:1 | — | — |
已生效 2021年8月27日
15:1
已生效 2021年8月18日
2:1
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI403.14万0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM352.68万0.00%787.4亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF204.23万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Value ETFIWN134.09万0.01%137.49亿 USD0.24%US$210.99-0.05%
Vanguard Russell 2000 ETFVTWO84.16万0.00%180亿 USD0.06%US$111.77-0.45%
iShares Micro-Cap ETFIWC45.89万0.04%13.17亿 USD0.60%US$179.6-1.13%
OneAscent Enhanced Small and Mid Cap ETFOASC22.35万0.23%9842.39万 USD1.38%US$34.21-0.58%
Avantis U.S. Small Cap Equity ETFAVSC21.2万0.01%30.79亿 USD0.25%US$70.06+0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCOneAscent Enhanced Small and Mid Cap ETFOASCAvantis U.S. Small Cap Equity ETFAVSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
